Xience V Stent Still Strong at 2 Years

September 24th, 2010

Xience V Stent Still Strong at 2 Years

Larry Husten, PHD

Two large trials presented at TCT continue to demonstrate the long-term superiority of the everolimus-eluting stent (EES) over the paclitaxel-eluting stent (PES).

Gregg Stone presented two-year outcomes from more than 3500 patients randomized in the SPIRIT IV trial to either the Xience V or the Taxus stents. At two years, the rate of target lesion failure — defined as cardiac death, target vessel MI, or ischemia-driven target lesion revascularization — was 9.9% in the Taxus group compared to 6.9% in the Xience V group (p<0.003). The rate of stent thrombosis was 1.25% in the Taxus group compared to 0.33% in the Xience V group (p=0.002).

In the two-year followup of the COMPARE trial, which included nearly 1800 patients, Peter Smits reported that the rate of death, nonfatal MI, and TVR was 13.7% in the Taxus group compared to 9.0% in the Xience group (p=0.0016). Definite or probable stent thrombosis was 3.9% in the Taxus group compared to 0.9% in the Xience group (p<0.0001).

CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

September 24th, 2010